Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public by merging with a Cormorant-sponsored SPAC. The combined company will continue developing drugs targeting various forms of mutated KRAS proteins that drive cancers.
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
The company expects the funding to bring it into the clinic and is also in partnering talks with academic institutions and biopharma companies, said co-founder Jonathan Lim, who previously led Ignyta.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
The startup created from Dana-Farber Cancer Institute announced today the closing of a $73 million Series A round of financing and a promising partnership with Roche.